Metsera
PublicMetsera is now publicly traded
The data on this page reflects Metsera's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Feb 3, 2025
Last Round
M&A
Nov 13, 2025
Est. Valuation at Exit
$7B
Total Funding Raised
$7.82B
Company Overview
Metsera is a biopharmaceutical company focused on developing innovative therapies for obesity and metabolic diseases.
Sector
Biotech
AI Layer
Non-AI
Keywords
Metsera Comparables
Compare Metsera with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| QL Biopharm | 76% | |
| Hummsa Biotech | 66% | |
| Adipo Therapeutics | 59% |
Metsera Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Nov 13, 2025 | ||||
| IPO | Feb 3, 2025 | ||||
| Series B | Nov 12, 2024 | ||||
| Series A | Apr 18, 2024 |
Key People
Founding team and executive leadership
Metsera Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Newpath Partners | Series B, Series A |
| Evercore ISI | IPO |
| Janus Henderson Group | Series B |
| SoftBank Investment Advisers | Series B, Series A |
| SymBiosis Capital Management | Series B |
| RA Capital Management | Series B |
| GV | Series B, Series A |
Metsera Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access